Maze Therapeutics Appoints Sekar Kathiresan, M.D., to its Board of Directors

Celsius Therapeutics Names Scientific Advisers

Septerna Appoints Jeffrey Finer, MD, PhD, as Chief Executive Officer

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-6291, Company’s First Mutant-Selective RAS(ON) Inhibitor

Decibel Therapeutics Announces Submission of Investigational New Drug (IND) Application for Lead Gene Therapy Candidate DB-OTO